BioMarin Pharmaceutical Inc. (BMRN) said it reached a stock purchase agreement to buy LEAD Therapeutics, Inc., a private drug discovery and early stage development company. Under the terms of the stock purchase agreement, BioMarin would pay to the stockholders of LEAD $18 million upfront and would pay an additional $11 million upon acceptance of the IND filing, and up to $68 million for development and launch milestones for LT-673. As a result of the deal, BioMarin expects to incur approximately $11.0 to $13.0 million in operating expenses and acquisition related charges in 2010. The acquisition is expected to be completed by mid-February 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.